Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the European spondyloarthritis (EuroSpA) research collaboration network

Pasoon Hellamand; Marleen G H Van de Sande; Lykke Midtbøll Ørnbjerg; Thomas Klausch; N Trokovic; Tuulikki Sokka-Isler; R Van Vollenhoven; D.C. Nordström; MJ Santos; Elsa Vieira-Sousa; A. G. Loft; Bente Glintborg; Mikkel Østergaard; U Lindström; Johan Karlsson Wallman; Brigitte Michelsen; B. Moeller; Raphael  Micheroli; Catalin Codreanu; C Moogosan; Karin Laas; Z Roter; M Tomsic; I Castrejon; M Pombo-Suarez; B Gudbjörnsson; T Love; Karen Minde Fagerli; K. Pavelka; Jakub Závada; G Kenar; H Yarkan-Tugsai; Merete Lund Hetland; I Van der Horst- Bruinsma

Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the European spondyloarthritis (EuroSpA) research collaboration network

Pasoon Hellamand, Marleen G H Van de Sande, Lykke Midtbøll Ørnbjerg, Thomas Klausch, N Trokovic, Tuulikki Sokka-Isler, R Van Vollenhoven, D.C. Nordström, MJ Santos, Elsa Vieira-Sousa, A. G. Loft, Bente Glintborg, Mikkel Østergaard, U Lindström, Johan Karlsson Wallman, Brigitte Michelsen, B. Moeller, Raphael Micheroli, Catalin Codreanu, C MoogosanKarin Laas, Z Roter, M Tomsic, I Castrejon, M Pombo-Suarez, B Gudbjörnsson, T Love, Karen Minde Fagerli, K. Pavelka, Jakub Závada, G Kenar, H Yarkan-Tugsai, Merete Lund Hetland, I Van der Horst- Bruinsma

Department for Rheumatology and Spine Diseases

Abstract

Background:
Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis)1,2. Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.

Original language	English
Publication date	2022
Publication status	Published - 2022
Event	The Thirteenth International Congress on Spondyloarthritides - Ghent, Belgium Duration: 7 Sept 2022 → 9 Sept 2022

Conference

Conference	The Thirteenth International Congress on Spondyloarthritides
Country/Territory	Belgium
City	Ghent
Period	07/09/2022 → 09/09/2022

Fingerprint

Dive into the research topics of 'Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the European spondyloarthritis (EuroSpA) research collaboration network'. Together they form a unique fingerprint.

Cite this

Hellamand, P., Van de Sande, M. G. H., Ørnbjerg, L. M., Klausch, T., Trokovic, N., Sokka-Isler, T., Van Vollenhoven, R., Nordström, D. C., Santos, MJ., Vieira-Sousa, E., Loft, A. G., Glintborg, B., Østergaard, M., Lindström, U., Wallman, J. K., Michelsen, B., Moeller, B., Micheroli, R., Codreanu, C., ... Van der Horst- Bruinsma, I. (2022). Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the European spondyloarthritis (EuroSpA) research collaboration network. Clinical and Experimental Rheumatology . Abstract from The Thirteenth International Congress on Spondyloarthritides, Ghent, Belgium.

Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the European spondyloarthritis (EuroSpA) research collaboration network. / Hellamand, Pasoon; Van de Sande, Marleen G H; Ørnbjerg, Lykke Midtbøll et al.
2022. Clinical and Experimental Rheumatology Abstract from The Thirteenth International Congress on Spondyloarthritides, Ghent, Belgium.

Research output: Contribution to conference › Conference abstract for conference › Research › peer-review

Hellamand, P, Van de Sande, MGH, Ørnbjerg, LM, Klausch, T, Trokovic, N, Sokka-Isler, T, Van Vollenhoven, R, Nordström, DC, Santos, MJ, Vieira-Sousa, E, Loft, AG, Glintborg, B , Østergaard, M, Lindström, U, Wallman, JK, Michelsen, B, Moeller, B, Micheroli, R, Codreanu, C, Moogosan, C, Laas, K, Roter, Z, Tomsic, M, Castrejon, I, Pombo-Suarez, M, Gudbjörnsson, B, Love, T, Fagerli, KM, Pavelka, K, Závada, J, Kenar, G, Yarkan-Tugsai, H, Hetland, ML & Van der Horst- Bruinsma, I 2022, 'Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the European spondyloarthritis (EuroSpA) research collaboration network', The Thirteenth International Congress on Spondyloarthritides, Ghent, Belgium, 07/09/2022 - 09/09/2022 pp. Clinical and Experimental Rheumatology .

Hellamand P, Van de Sande MGH, Ørnbjerg LM, Klausch T, Trokovic N, Sokka-Isler T et al.. Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the European spondyloarthritis (EuroSpA) research collaboration network. 2022. Abstract from The Thirteenth International Congress on Spondyloarthritides, Ghent, Belgium.

Hellamand, Pasoon ; Van de Sande, Marleen G H ; Ørnbjerg, Lykke Midtbøll et al. / Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the European spondyloarthritis (EuroSpA) research collaboration network. Abstract from The Thirteenth International Congress on Spondyloarthritides, Ghent, Belgium.

@conference{b7ab8ffe889a4bc1a7b76c6f416dd500,

title = "Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the European spondyloarthritis (EuroSpA) research collaboration network",

abstract = "Background: Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis)1,2. Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.",

author = "Pasoon Hellamand and {Van de Sande}, {Marleen G H} and {\O}rnbjerg, {Lykke Midtb{\o}ll} and Thomas Klausch and N Trokovic and Tuulikki Sokka-Isler and {Van Vollenhoven}, R and D.C. Nordstr{\"o}m and MJ Santos and Elsa Vieira-Sousa and Loft, {A. G.} and Bente Glintborg and Mikkel {\O}stergaard and U Lindstr{\"o}m and Wallman, {Johan Karlsson} and Brigitte Michelsen and B. Moeller and Raphael Micheroli and Catalin Codreanu and C Moogosan and Karin Laas and Z Roter and M Tomsic and I Castrejon and M Pombo-Suarez and B Gudbj{\"o}rnsson and T Love and Fagerli, {Karen Minde} and K. Pavelka and Jakub Z{\'a}vada and G Kenar and H Yarkan-Tugsai and Hetland, {Merete Lund} and {Van der Horst- Bruinsma}, I",

note = "COPECARE; The Thirteenth International Congress on Spondyloarthritides ; Conference date: 07-09-2022 Through 09-09-2022",

year = "2022",

language = "English",

pages = "Clinical and Experimental Rheumatology ",

}

TY - ABST

T1 - Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the European spondyloarthritis (EuroSpA) research collaboration network

AU - Hellamand, Pasoon

AU - Van de Sande, Marleen G H

AU - Ørnbjerg, Lykke Midtbøll

AU - Klausch, Thomas

AU - Trokovic, N

AU - Sokka-Isler, Tuulikki

AU - Van Vollenhoven, R

AU - Nordström, D.C.

AU - Santos, MJ

AU - Vieira-Sousa, Elsa

AU - Loft, A. G.

AU - Glintborg, Bente

AU - Østergaard, Mikkel

AU - Lindström, U

AU - Wallman, Johan Karlsson

AU - Michelsen, Brigitte

AU - Moeller, B.

AU - Micheroli, Raphael

AU - Codreanu, Catalin

AU - Moogosan, C

AU - Laas, Karin

AU - Roter, Z

AU - Tomsic, M

AU - Castrejon, I

AU - Pombo-Suarez, M

AU - Gudbjörnsson, B

AU - Love, T

AU - Fagerli, Karen Minde

AU - Pavelka, K.

AU - Závada, Jakub

AU - Kenar, G

AU - Yarkan-Tugsai, H

AU - Hetland, Merete Lund

AU - Van der Horst- Bruinsma, I

N1 - COPECARE

PY - 2022

Y1 - 2022

N2 - Background: Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis)1,2. Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.

AB - Background: Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis)1,2. Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.

M3 - Conference abstract for conference

SP - Clinical and Experimental Rheumatology

T2 - The Thirteenth International Congress on Spondyloarthritides

Y2 - 7 September 2022 through 9 September 2022

ER -